PT  - JOURNAL ARTICLE
AU  - Lin, Dan-Yu
AU  - Gu, Yu
AU  - Zeng, Donglin
AU  - Janes, Holly E.
AU  - Gilbert, Peter B.
TI  - Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection
AID  - 10.1101/2021.04.16.21255614
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.16.21255614
4099  - http://medrxiv.org/content/early/2021/04/17/2021.04.16.21255614.short
4100  - http://medrxiv.org/content/early/2021/04/17/2021.04.16.21255614.full
AB  - Although interim results from several large placebo-controlled phase 3 trials demonstrated high vaccine efficacy (VE) against symptomatic COVID-19, it is unknown how effective the vaccines are in preventing people from becoming asymptomatically infected and potentially spreading the virus unwittingly. It is more difficult to evaluate VE against SARS-CoV-2 infection than against symptomatic COVID-19 because infection is not observed directly but rather is known to occur between two antibody or RT-PCR tests. Additional challenges arise as community transmission changes over time and as participants are vaccinated on different dates because of staggered enrollment or crossover before the end of the study. Here, we provide valid and efficient statistical methods for estimating potentially waning VE against SARS-CoV-2 infection with blood or nasal samples under time-varying community transmission, staggered enrollment, and blinded or unblinded crossover. We demonstrate the usefulness of the proposed methods through numerical studies mimicking the BNT162b2 phase 3 trial and the Prevent COVID U study. In addition, we assess how crossover and the frequency of diagnostic tests affect the precision of VE estimates.Summary We show how to estimate potentially waning efficacy of COVID-19 vaccines against SARS-CoV-2 infection using blood or nasal samples collected periodically from clinical trials with staggered enrollment of participants and crossover of placebo recipients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThis work was supported by the NIH grants R01 AI029168, R01 GM124104, P01 CA142538, and UM1 AI068635.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A https://dlin.web.unc.edu/software/idove/